Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03127761 · ClinicalTrials.gov registry record
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
A clinical trial of Multiple Myeloma, sponsored by Center for International Blood and Marrow Transplant Research.
- Recruiting
- Registry status
- 544
- Enrollment target
- 1
- Study location
NCT03127761: Recruiting study of Multiple Myeloma, sponsored by Center for International Blood and Marrow Transplant Research.
NCT03127761 is a study of Multiple Myeloma that is actively recruiting participants, run by Center for International Blood and Marrow Transplant Research. The registered enrollment target is 544 participants, roughly in line with the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03127761, a study of Multiple Myeloma, is actively recruiting participants, sponsored by Center for International Blood and Marrow Transplant Research.
- RECRUITING
- Registry status
- 544 participants
- Enrollment target
- 1
- Study location
Study Summary
Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT). Allogeneic HCT (alloHCT) is the only potentially curative therapy available to patients with MM. However, the significant morbidity and mortality of this procedure historically limited its application in older patients. Thus, although potentially curative, standard risk MM patients have excellent prognoses in the era of novel therapies which reduces the overall benefit of alloHCT. However, because the outcomes for high-risk MM remain poor despite the best available standard therapies (overall survival of 24-36 months), initial data suggest that alloHCT should be explored in this subset.
Primary Outcome
Compare five-year overall survival between the alloHCT cohort and an age and disease risk matched cohort of autoHCT patients
Conditions Studied
Interventions
- OTHER Allogeneic Hematopoietic Stem Cell Transplant
Study Locations (1)
Minnesota
- Center for International Blood and Marrow Transplant Research - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 544 participants |
| Start Date | 2017-07-25 |
| Est. Completion | 2028-04 |
What NCT03127761 shows while recruiting
NCT03127761 is an observational study that tracks outcomes without assigning an intervention. The registered 544 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Allogeneic Hematopoietic Stem Cell Transplant is the first listed.
NCT03127761 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03127761 about?
NCT03127761 is a clinical study titled "Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma". Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT). Allogeneic HCT (alloHCT) is the only potentially curative therapy available to patients wi...
What is the current status of trial NCT03127761?
This trial is currently recruiting. The enrollment target is 544 participants. The study started on 2017-07-25. Estimated completion is 2028-04.
What conditions does trial NCT03127761 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03127761?
The interventions under investigation include: Allogeneic Hematopoietic Stem Cell Transplant (OTHER).
Who is sponsoring clinical trial NCT03127761?
This trial is sponsored by Center for International Blood and Marrow Transplant Research, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03127761 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03127761's enrollment target sits among peer trials
544 40th of 438 higher than 399 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04378790 · 544 participants · Phase 3
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
- NCT06118502 · 544 participants · NA
A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse
- NCT06170437 · 544 participants · NA
Smoke-free Home Study in Subsidized Housing
- NCT06785064 · 544 participants · NA
Optimizing an Extended Care Intervention to Promote Weight Loss Maintenance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI